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Abstract
Background: A high proportion of the costs for respiratory diseases are generated by a relatively small group of patients with
severe disease (recognized or unrecognized) or complex problems that include multimorbidity, at-risk behaviors, and socioeconomic
disadvantage. These patients often struggle to engage with the structured, proactive, care approaches for chronic disease management
advocated for asthma and chronic obstructive pulmonary disease (COPD), resulting in repeated emergency use of both primary
and secondary health care. An integrated approach for the management of complex patients, incorporating both specialist and
primary care teams’ expertise, may be effective in improving outcomes for such high-risk patients. However, the evidence is
mixed, and there is a need for evaluation of models of integrated care in routine “real-world” clinical settings.
Objective: This mixed-methods protocol examines the implementation of a novel integrated care model for patients with airways
disease and undifferentiated breathlessness by using both quantitative and qualitative evaluation of processes, patient and health
care professional experiences, and clinical outcomes throughout the clinic cycles. It aims to establish whether Modern Innovative
Solutions to Improve Outcomes in Asthma, Breathlessness, and Chronic Obstructive Pulmonary Disease (MISSION ABC),
including innovative diagnostic and self-management tools, can deliver improvements in health service use and clinical outcomes
for the different patient groups (asthma, breathlessness, and COPD) and compares the 12-month period prior to the first patient
visit and the 6-month period following the last visit.
Methods: A combination of study designs is required to evaluate all aspects of the service: participatory action research approach,
involving real-time evaluation at each clinic to inform subsequent clinics; before-and-after study for patient outcomes before and
after clinic attendance; and qualitative methods (interviews and focus groups).
Results: The results will be compiled and published in April 2019.
Conclusions: Evaluation of the clinic cycles will include consideration of qualitative data from patients, carers, and health care
professionals in addition to quantitative outcomes for service implementation and patient factors. The long-term impact of the
service will be evaluated using clinical and health service outcomes.
International Registered Report Identifier (IRRID): DERR1-10.2196/9228
(JMIR Res Protoc 2019;8(3):e9228)   doi:10.2196/resprot.9228
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Introduction
The Burden of Disease
Respiratory diseases are highly prevalent and a major cause of
health care utilization in Wessex, United Kingdom. The two
most common chronic respiratory diseases—asthma and chronic
obstructive pulmonary disease (COPD)—are underdiagnosed,
are major drivers to acute care episodes, and show poor clinical
outcomes compared to other conditions in many areas of the
region.
More than 1 million people in the United Kingdom are
diagnosed with COPD. There is still a “prevalence gap” between
the expected and actual prevalence of COPD among general
practitioner (GP) practices, and in 13% of the UK population
aged over 35 years, COPD is undiagnosed. These “missing
millions” will likely need acute care, and 15% will only be
diagnosed on admission to the hospital [1]. More than 5 million
people are affected by asthma in the United Kingdom, and more
than 500,000 people have severe or difficult-to-control asthma,
of which 70% have an allergic subtype [2]. Patients with severe,
exacerbation-prone disease are more likely to be admitted to
the hospital and account for the most significant utilization of
health services. Both COPD and asthma are associated with
increased morbidity and mortality and can lead to disabling
symptoms that impact the patient’s quality of life and well-being.
COPD is the fifth most common cause of death in the United
Kingdom, resulting in approximately 25,000 deaths annually.
It is also the second most common cause for hospital admission
in the United Kingdom, and 35% of patients are readmitted
within 30 days. In 2009, asthma accounted for 1,131 deaths in
the United Kingdom, triggering a National Audit of Asthma
Deaths. The National Review of Asthma Deaths [3] published
in 2014 concluded that many areas in the diagnosis and care of
patients with asthma such as access to timely and appropriate
care, use of personalized action plans, and appropriate severity
assessment can be improved to reduce unnecessary deaths.
The National Health Service spends £2 billion per year on the
management of asthma and COPD [4]. Both conditions have
direct financial costs, additional social costs through time off
work and reduced productivity, and further indirect costs through
reduced quality of life and well-being. The annual health care
expenditure on COPD is more than £800 million (£1.3 million
per 100,000 population). The treatment of severe,
exacerbation-prone COPD (exacerbation is defined as an acute
worsening of respiratory symptoms requiring an increase in
therapy [5]) costs ten times more than that of mild disease.
COPD is responsible for 24 million lost working days annually,
costing the economy £2.7 billion. Nearly 80% of costs for
asthma are related to the treatment of poorly controlled disease
[6], which amounts to over £1 billion per annum [2] as a direct
cost and £6 billion as an indirect cost to society (time off work
and lost productivity). Four of the top 10 most expensive drugs
covered by the National Health Service are inhaled medications
for asthma and COPD.
Shortness of breath is recorded in 1% of primary care
consultations [7] and 10% of the population affected by chronic
breathlessness symptoms [8]. This proportion increases to
one-third in the elderly, with a significant impact on the
functional status and health-related quality of life [9]. Although
breathlessness is a symptom of many diseases, the referral and
management systems are often specific to the diagnosis. Thus,
patient visits to more than one outpatient department for
breathlessness may result in an onerous clinical journey and
underrecognition of comorbidity [10].
A New Model of Care
A high proportion of the costs for respiratory diseases is
generated by a relatively small group of patients with severe
disease (recognized or unrecognized) or complex problems that
include multimorbidity, at-risk behaviors, and socioeconomic
disadvantage. Such patients often struggle to engage with the
structured, proactive care approach to chronic disease
management advocated for asthma and COPD, resulting in
repeated emergency health care use of both primary and
secondary care. An integrated approach for the management of
complex patients, incorporating both specialist and primary care
teams’ expertise, may be effective in improving outcomes for
such high-risk patients. However, the evidence is mixed, and
there is a need for evaluations of models of integrated care in
routine “real-world” clinical settings.
The Modern Innovative Solutions Improving Outcomes in
Asthma, Breathlessness, and COPD (MISSION ABC) system
is a new model of care that starts by identifying at-risk patients
and subsequently streamlines their care, incorporating new
technology to improve management of airways disease. Patients
are identified using criteria that indicate poor disease control,
a heavy burden of symptomatology, or unidentified disease.
The patients are then delivered streamlined assessment and care
in a one-stop (MISSION Rapid) or two-stop clinic journey
(Rapid plus MISSION Investigation clinics). MISSION Rapid
clinics, organized in the community, promote integration of
primary and specialist teams, wider respiratory multidisciplinary
teams, psychological and well-being services, charity, and
patient group representation. Each patient’s diagnosis is
reviewed using spirometry, fractional exhaled nitric oxide
(FeNO), and oscillometry (each provided by a specialist
respiratory physiologist) along with a specialist medical review;
the reasons for poor disease control are explored (unidentified
comorbidity, difficulties in self-management, coexisting
anxieties, or social stressors), and the medications are optimized
using local and national guidelines. All patients were offered
personalized self-management plans. Patients who are stable
are supported in the management of their disease through
education (myCOPD [11] or myAsthma [12]) and upskilling of
lead health care professionals (HCPs) and champions in GP
practices through competency-based training, including
spirometry and comorbid disease management. The model of
patient flow through the MISSION service is shown in Figure
1 (COPD), Figure 2 (asthma), and Figure 3 (breathlessness).
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Figure 1. COPD cohort flow chart with study outcomes shown in yellow boxes. COPD: chronic obstructive pulmonary disease; GRASP: Guidance
on Risk Assessment in Stroke Prevention; CAT: COPD Assessment Test; ASK-12: Adherence Starts with Knowledge questionnaire-12; PAM: Patient
Activation Measure; WBPA: weight-bearing physical activity; MDT: multidisciplinary team; GP: general practitioner; PIS: patient information sheet;
HCP: health care professional; BMI: body mass index; SF-36: Short Form Health Survey-36; VSAQ: Veterans Specific Activity Questionnaire; EQ5d:
EuroQoL-5D; WPAI: Work Productivity and Activity Impairment.
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Figure 2. Asthma cohort flow chart with study outcomes shown in yellow boxes. GRASP: Guidance on Risk Assessment in Stroke Prevention; CAT:
Chronic obstructive pulmonary disease Assessment Test; ASK-12: Adherence Starts with Knowledge questionnaire-12; PAM: Patient Activation
Measure; WBPA: weight-bearing physical activity; MDT: multidisciplinary team; GP: general practitioner; PIS: patient information sheet; HCP: health
care professional; BMI: body mass index; EQ5d: EuroQoL-5D; WPAI: Work Productivity and Activity Impairment; ACQ: Asthma Control Questionnaire;
TLA: temperature-controlled laminar airflow.
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Figure 3. Breathlessness cohort flow chart with study outcomes shown in yellow boxes. COPD: chronic obstructive pulmonary disease; GRASP:
Guidance on Risk Assessment in Stroke Prevention; CAT: COPD Assessment Test; ASK-12: Adherence Starts with Knowledge questionnaire-12;
PAM: Patient Activation Measure; WBPA: weight-bearing physical activity; MDT: multidisciplinary team; PIS: patient information sheet; HCP: health
care professional; BMI: body mass index; SF-36: Short Form Health Survey-36; VSAQ: Veterans Specific Activity Questionnaire; EQ5d: EuroQoL-5D;
WPAI: Work Productivity and Activity Impairment.
A New Service for Asthma Patients
We will implement a novel clinical pathway for asthma patients
that includes diagnosis, assessment, and adjustment of treatment;
maintains control using complementary innovations and models
of care; and draws on resources and skills from primary,
secondary, and tertiary care.
We will use Guidance on Risk Assessment in Stroke Prevention
(GRASP) [13] searches across Wessex Clinical Commissioning
Groups to identify patients who are likely to have asthma. When
a diagnosis is established, we will identify patients whose
conditions are not well controlled (eg, frequent exacerbations,
emergency department visits, hospital admissions, use of three
or more controller medications, and use of frequent short-acting
bronchodilators). These patients’ records will be reviewed by
specialist nurses and, if appropriate, in MISSION clinics. The
clinics will provide timely diagnosis with cutting-edge
technology, including FeNO and airway oscillometry,
assessment of disease control and comorbidity, an education
session, and a self-management plan through written and mobile-
or Web-based solutions, where appropriate. Inhaler technique
and adherence will be assessed, and patients will be encouraged
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to maintain good practices with the Flo-Tone device and
inhaler-use monitor [14]. Patients requiring more urgent care
will be assessed and treated by a rapid response team.
After the patients visit the MISSION Asthma clinic, the
following tools will be used to enable continuous assessment,
adjustment, and maintenance of disease control: Message
Dynamics portal [15], Clinitouch system [16,17], myAsthma,
Airsonett [18,19], smoking cessation, and education. Message
Dynamics and Clinitouch use communications technology across
multiple platforms to monitor symptoms, allowing early
recognition of deterioration. By combining these approaches,
HCPs can target patients early in an exacerbation event by using
community-based management, thereby reducing the need for
admission and the cumulative burden of symptoms on the
patient. MyAsthma is a self-management online platform
providing education and a symptom diary to encourage patients
to manage their asthma. The Airsonett device is a laminar
airflow device that reduces allergen exposure in patients with
severe allergic asthma and may increase control and reduce
healthcare utilization.
Chronic Obstructive Pulmonary Disease
Patients will be identified through the use of GRASP COPD
[13] and directed to the MISSION COPD clinics. At the clinics,
patients will be reviewed according to the following the National
Institute for Health and Care Excellence (NICE) quality
framework standards [20]:
• Diagnosis: Thorasys [21] and exhaled nitric oxide from
Niox [22]
• Medicine optimization: Flo-Tone device
• Smoking cessation
• Self-management: MISSION Self-Management Plans and
myCOPD (similar to myAsthma but including online
pulmonary rehabilitation program)
After the initial assessment, all patients will be encouraged and
supported to keep themselves active while using myPR, the
online pulmonary rehabilitation tool designed by my mHealth.
Patients found to be at high risk of disease exacerbation (based
on clinical characteristics or prior health care usage, decided by
the senior clinician at the clinic) at the MISSION will be
encouraged to report their symptoms via the Message Dynamics




Patients with breathlessness who do not have an established
diagnosis will be identified from the GP and practice records
by using GRASP case-finding tools and will be offered the same
high-quality diagnostic service as that offered to patients with
asthma and COPD. In the MISSION clinic, these patients will
be assessed using our novel diagnostic tools with additional
availability of electrocardiogram recordings and a point-of-care
test to identify any strain on the cardiac muscle by measuring
the B-natriuretic peptide level. If asthma or COPD is identified,
patients will join the respective care pathways. If a cardiac cause
is identified, the patient will either be referred to the heart failure
clinic or discharged to their GP. If the cause is a syndrome that
leads to difficulty in breathing or deconditioning, patients will
be offered an appointment with a MISSION ABC
physiotherapist who will deliver targeted breathing retraining
and discuss the benefits of maintaining exercise.
Innovations Embedded With New Models of Care
A brief outline of the innovations is provided below, followed
by a description of how these innovations are incorporated into
the new service model.
Digital Platforms to Identify and Monitor Patients
GRASP is a tool created by PRIMIS (Nottingham, United
Kingdom) in conjunction with the University of Nottingham,
United Kingdom. The tool examines GP records based on a
chosen set of read codes and generates a search list tailored to
the demands of the interrogator. This tool has been successfully
used to generate patient lists for a variety of projects for the
Wessex Academic Health Science Network (Southampton,
United Kingdom).
Patient Self-Management and Monitoring
The following tools were used for patient self-management and
monitoring:
MymHealth (myCOPD and myAsthma)
MymHealth [23] is a Web-based self-management system
designed to support self-care in people with COPD and asthma.
The system can be easily and securely accessed online by
patients and HCPs. It facilitates the effective recognition of
symptoms, inhaler technique, and management of medicines.
It is an easy-to-use system that promotes patients to manage
their COPD or asthma at home. Patients can also access an
electronic platform containing a comprehensive, guided, 6-week
pulmonary rehabilitation program to improve their health and
quality of life.
Message Dynamics
Message dynamics [15] is a multiaward-winning provider of
low-cost telehealth solutions through an app or a traditional
telephone. Patients respond to a simple questionnaire that aims
to detect symptoms of exacerbation.
Clinitouch
Clinitouch [16,17] is an app-based system that uses
disease-control questionnaires and Bluetooth-enabled blood
pressure and oxygen-saturation monitors that allow clinicians
to remotely monitor their patient cohort. The patient is supported
with an online self-management plan.
Technical Innovations
Diagnosis
The following tools were used for diagnosis:
Niox
This is a point-of-care testing device that measures exhaled
nitric oxide [22]. It is a marker of eosinophilic
corticosteroid-responsive inflammation that can predict loss of
control in patients with asthma and supports phenotyping of
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patients with asthma and COPD. This tool was recently approved
by NICE for the diagnosis of asthma [24].
Thorasys
This is a portable diagnostic tool that measures airways
oscillometry, airway resistance, and obstruction independent of
patient effort, thereby providing an accurate diagnosis with
minimal effort [21,25]. Oscillometry offers an alternative
method to traditional methods such as spirometry for assessing
airway function. It has the potential to identify abnormal airway
function that spirometry may be unable to detect, especially
defects residing in the smaller airways. Oscillometry is
particularly useful in patients who are unwilling or unable to
adequately comply with the technical requirements of spirometry
or when spirometry is considered inappropriate or
contraindicated.
Treatment Improvement
For improving treatment, the following tools were used:
Clement-Clark Flo-Tone
This is a simple device that fits within the mouthpiece of any
inhaler [26]. When the optimum inspiratory flow rate is achieved
for that device, a musical note is heard. This immediately
provides feedback to the patient but can also be recorded via a
mobile phone app to inform the HCP.
Airsonett
The Airsonett device [19] can improve care of patients with
severe allergic asthma and poorly controlled symptoms. The
laminar airflow system, placed above the patient during sleep,
vastly reduces aeroallergen exposure, resulting in fewer
symptoms and improves disease control.
Service Model Innovations - MISSION COPD and MISSION
Asthma
This is an award-winning, novel way of delivering highly
specialized multidisciplinary asthma and COPD care in the
community, providing specialist clinics to rapidly identify
patients with asthma and COPD and then to assess and adjust
management plans and empower patients through education
[27]. A pathway has been designed to improve patient care and
safety and prevent hospital admissions and nonelective visits
in primary care.
Aims and Objectives
This study aimed to examine (1) the implementation of a novel
integrated care model for patients with airways disease and
undifferentiated breathlessness using both quantitative and
qualitative evaluation of processes and patient and HCP
experiences and (2) clinical outcomes throughout the clinic
cycles driving a continuous improvement process, evaluated
through participatory action research. We also aimed to establish
whether MISSION ABC, including innovative diagnostic and
self-management tools, can deliver improvements in health
service use and clinical outcomes for different patient groups
(asthma, breathlessness, and COPD) by comparing the 12-month
period prior to the first patient attendance and the 6-month
period following attendance, by using regressional analyses to




The main focus of this project is to deliver a
quality-improvement project—MISSION ABC—that has been
informed by three prior projects. This protocol of predominantly
Participatory Action Research [28] accompanies the project to
record the delivery, iterative changes to the project, and
outcomes and ensure rigor in the reporting of these parameters.
Accompanying innovations are embedded in the project to
encourage a culture of growth amongst small- and medium-sized
enterprises within the health care system. Outcomes related to
these innovations are exploratory, not designed to be powered,
and will not be presented with a control group.
A combination of study designs are required to evaluate all
aspects of the service:
1. Participatory Action Research approach involving real-time
evaluation at each clinic to inform subsequent clinics
2. Cohort (longitudinal) data approach for clinic- and
patient-level service use and outcome indicators
3. Before-and-after study of patient outcomes before and after
the clinic visit
4. Qualitative methods (interviews and focus groups)
Participatory Action Research Approach
Data Evaluation
A list of all the data that will be evaluated on a cyclical basis is
provided below. These include quantitative data and themes
that will be explored qualitatively with HCPs, patients, and
carers to inform the next clinic. Issues for improvement, changes
to the clinic process, and the rationale for changes will be
recorded in a learning log. The impact of changes will be
reviewed following the subsequent clinic visit and from any
further feedback from qualitative interviews and focus groups.
Fidelity to the original project plans and reasons for the changes
made will be reported as part of the project analysis.
This list of outcomes is not exhaustive, as the cyclical approach
may identify other key areas that are important to monitor. If
additional questionnaires or methods of data collection from
patients are required, they will be submitted to the ethics
committee as an amendment.
Clinic Process
• Acceptability of clinic delivery model by patients, carers,
and HCPs including host GP surgeries
• Perceived appropriateness of the clinic by the patient group,
judged by HCPs delivering the clinic services and the host
surgeries
• Primary care staff attendance at the clinic (number and
position)
• Number of patients identified as appropriate for the clinic
• Attendance rates at each offered session
Diagnostics
• Number of new or modified diagnoses made at the clinic
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• Number of patients where the British Thoracic Society
Asthma stage or Global Obstructive Lung Disease (GOLD)
COPD classification [5] is changed following discussion
by the multidisciplinary team
• Number of new comorbidities newly identified
Education and Supported Self-Management
• Uptake of the education sessions when offered and reasons
for decline, when given
• Acceptability of education sessions by participants and
carers
• Confidence in self-management measured before and after
the clinic visit and after subsequent education sessions
• Changes in treatment adherence before and after the
intervention, measured using the Adherence Starts with
Knowledge questionnaire-12 (ASK-12) [29,30] and a
prescription reconciliation
• Uptake of the HCP education program
• Acceptability of the HCP education program by participants
Use of Treatment Tools
• Number of patients who showed improved inhaler
technique, as judged after the first clinical encounter
• Number of patients with improved technique who sustained
the improvement at subsequent review when prompted by
clinical need
• Number of quit-for-life reviews that resulted in a quit
attempt, and if these quit attempts resulted in sustained
cessation at 6 months
• Number and type of inhalers prescribed before and after
the intervention
Remote Monitoring
• Number of patients identified for remote monitoring
• Number of triggers on remote monitoring that progress to
a clinically significant exacerbation
• Number of reported delays in reporting exacerbation due
to the presence of remote monitoring
• Incidences where the carer of a family member is required
to facilitate use of remote monitoring
Additional Balancing Measures
• Number of GP or practice nurse sessions changed or
cancelled to host the clinic
• Additional costs such as childcare or extra travel incurred
by the delivery team when care is delivered remote to their
usual place of work or outside the usual working week
• Number of GP, community nurse, or emergency department
episodes resulting from remote monitoring
• Number of secondary care referrals resulting from the
program
Patient and Health Service Use Outcomes (Longitudinal
Follow-Up)
Changes in quality-of-life measures prior to the clinic visits and
at 3 and 6 months were measured with generic or
disease-specific quality-of-life questionnaires. These
questionnaires evaluated the following:
• Changes in productivity and activation measures prior to
the clinic visit and at 6 months
• Changes in disease control, quality of life, and comorbidity
measured by disease-specific questionnaires and
unscheduled health care utilization (eg, emergency GP
visits, out-of-hours/111 calls, hospital admissions, and
emergency department attendances).
• Exacerbations in the 6 months before and after MISSION
attendance
• Cost of delivery of the clinic model
Innovations
Thorasys
• Number of new diagnoses of airways disease made after
use of the Thorasys device
• Number of patients who are unable to complete reproducible
spirometry who have reproducible results with Thorasys
• Number of unusable results
• Perceived ease of use by health care professionals
Flo-Tone
• Number of patients given the Flo-Tone device
• Number of patients using the Flo-Tone device following
reviews, when prompted by clinical need
• Number of patients deemed to have improved the
pressurized metered dose inhaler technique through use of
Flo-Tone
Airsonett
• Number of patients suitable for use of the Airsonett
temperature-controlled laminar airflow device
• Number of patients offered the device who accepted its use
• Change in exacerbation frequency in the 6 months before
and after the use of the Airsonett device
• Number of patients who elect for ongoing use of the device
after 6 months
MyCOPD and MyAsthma
• Uptake of online, supported self-management provided by
my mHealth
• Acceptability of online-supported self-management by the
patient and family or carer
• Number of patients using online pulmonary rehabilitation
• Number of patients who access the online self-management
plan
Message Dynamics
• Acceptability of the treatment by patient
• Acceptability of the treatment by HCPs
• Number of positive triggers that can be managed by advice
only
• Number of positive triggers that require clinical review,
and type of review chosen
• Number of triggers that result in a clinically significant
exacerbation
• Duration of monitoring required by the patient, as judged
by the clinical team
Clinitouch
• Acceptability of the treatment by patient
• Acceptability of the treatment by HCPs
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• Number of positive triggers generated by Bluetooth device
readings
• Number of positive triggers generated by symptom scores
• Number of positive triggers that can be managed by advice
only
• Number of positive triggers that require clinical review,
and type of review chosen
• Number of triggers that result in a clinically significant
exacerbation
• Duration of monitoring required by the patient, as judged
by the clinical team
Study Participants
Study Setting
MISSION Clinics will be held in at least 10 surgeries within
the Wessex region. The clinic services will be delivered by an
integrated team of primary (primary care nurses and GPs),
secondary (respiratory nurses, physiotherapists, physiologists,
and registrars), and tertiary (regional specialist asthma service)
care providers with delivery of care across all three sectors.
Overall Description of Study Participants
Adult patients (aged ≥ 16 years) with poorly controlled asthma
or COPD as well as those with undifferentiated breathlessness
will be identified using GRASP tools; referred from a
community pharmacist or by their primary care team; and invited
to a local MISSION clinic with a relative, friend, or carer in
attendance, if they wish. All eligible attendees will be invited
to participate in the study. The sample size will be determined
by the uptake of appointments and clinic capacity but is
projected to be 500 patients and 15 HCPs.
Eligibility Criteria
All patients who have attended the MISSION ABC clinic will
be considered eligible to partake in the study if they are able to
provide informed consent. Family or carers will be asked to
participate in the qualitative research if they have accompanied
the patient to an educational event. Health care participants from
host surgeries or visiting from outside organizations will also
be eligible for participation in the participatory action research
and qualitative aspects of the study. An individual’s participation
in any applicable aspect of the MISSION will be unaffected by
their decision to consent.
Study Procedures
Screening and Enrollment
All potential participants will be sent a Participant Information
Sheet by post or email after initial contact. If they are suitable
for the clinic, they will be screened for their ability to give
informed consent. If they are able to consent and wish to do so,
they will be enrolled at a clinic. It will be made clear to each
participant that their care is unaffected by their decision to enroll
in the study.
Randomization
There will be no randomization.
Study Assessments
The study assessments are summarized in Figures 1, 2, and 3
(COPD, asthma, and breathlessness, respectively).
Patient Assessments
Patient Characteristics
• Age, height, weight, and body mass index recorded at the
first clinic visit
• New or changed diagnoses recorded for each patient seen
• Any change in British Thoracic Society Asthma Stage or
GOLD COPD classification, as judged by the
multidisciplinary team for those with newly diagnosed or
established asthma or COPD
• Number and type of comorbidities pre-existing and
identified through the MISSION process
• Occupation, employment status, and postal code
• Smoking status
Disease Control, Disease-Related Quality of Life, and
Activation Measures
All baseline questionnaires will be sent to patients before the
first clinical encounter. If they choose not to participate in the
research study, these questionnaires will still aid in clinical
decision-making and will be retained in the clinical record. If
patients need assistance in completing these questionnaires, it
will be offered at the first clinic visit. The questionnaires used
are listed below:
• A baseline exploratory semistructured questionnaire
designed by the team to explore disease impact and
behaviors
• Disease-specific control questionnaires (Asthma Control
Questionnaire [31] and COPD Assessment Test [32]):
Baseline measure and then repeated at 3 and 6 months after
the first clinical encounter
• Exercise tolerance and symptom measures: Veterans
Specific Activity Questionnaire [33], Nijmegen
questionnaire [34], and Self Evaluation of Breathing
Questionnaire [35] at baseline and repeated at 3 and 6
months
• Use of unscheduled care (including GP visits), steroids or
antibiotics for exacerbations, and hospital admissions
recorded for each patient at 3 and 6 months compared to
their 6 and 12 months visits prior to the MISSION process
• Measures of activation and medicine compliance (ASK-12
and Patient Activation Measure [36]) at baseline and 3 and
6 months
• Productivity measures (EuroQoL-5D [37] and Work
Productivity and Activity Impairment [38]) at baseline and
6 months
• Quality of life scores: Short Form Health Survey-36
(generic) [39], Asthma Quality of Life Questionnaire
(AQLQ) for asthma [40], and St George’s Respiratory
Questionnaire for COPD [41]
• Number of quit-for-life reviews that have resulted in a quit
attempt at 3 and 6 months
• Prescription reconciliation at 6 months before and after the
clinic visit to assess medication usage
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Patient’s Experience of MISSION ABC
• Semistructured questionnaires exploring patient experiences,
completed after each clinical encounter
• Qualitative interviews will be completed with 10% of
patients who participate in the study, exploring factual,
structural, interpersonal, intrapersonal, and contextual
influences on the experience of receiving the new service.
Discussions will be transcribed using a transcription service
and analyzed using a thematic analysis to compare themes.




• Acceptability of use of the new diagnostic devices (Niox,
FeNO, and Thorasys) as well as the management tools
(Flo-Tone and Airsonett) will be analyzed through
structured questionnaires given to the clinic staff.
• Instances where a diagnosis is made as a result of the use
of these devices, which would not be identified by standard
investigation, will be recorded. If these events are unclear,
the decision of the senior clinician present will be
considered.
• Equipment breakdowns or technical difficulties will be
recorded as a clinic process outcome.
• Proportion of patients who have continued to use supportive
devices at the follow-up review will be calculated.
Digital Platforms
• HCPs’ and patients’ experiences of the use of digital
platforms will be assessed using semistructured
questionnaires.
Assessment of Monitored, Supported Follow-Up
• Number of patients offered remote monitoring, and
proportion of patients who accept
• Proportion of patients with access to smartphones or home
internet
• Number of triggers generated on remote monitoring
• Proportion of triggers that result in a clinically significant
exacerbation
• Proportion of triggers that require a patient review
• Proportion of clinically significant exacerbations that are
managed in the community
• Proportion of responses to remote monitoring that are
completed by the patient
• Rate of drop outs from remote monitoring and the stated
reason
• Patient and primary care experiences of using remote
monitoring measured by a semistructured questionnaire
Assessment of Health Care Professionals’ Experiences
In addition to the assessments listed above, a sample of 10 HCPs
will be invited to participate in a focus group that will explore
their views on the acceptability, appropriateness, and feasibility
of the program. An independent interviewer will ask them to
comment on their perceived barriers and drivers for further
implementation of the program. The focus group will be
recorded, but the responses will be anonymized. After
transcription, the interviews will be analyzed for themes.
Participatory Action Research Outcomes
The core team will meet monthly to evaluate the clinic delivery
process. Using patient and HCP feedback questionnaires, pitfalls
and issues of the clinical process will be examined using
Plan-Do-Study-Act analysis. When changes are made, a further
review will take place in the following meeting until the change
is deemed to have provided a positive impact on the process.
These analyses will be recorded in a learning log.
Additional Process Outcomes
• Rate of uptake of the clinic by primary care providers when
offered
• Expenditure in delivery of the clinic services including
staffing costs, consumables, and unexpected expenses
Balancing Measures
We acknowledge that enhanced investigation and intervention
may increase costs to health care providers in the
short-to-medium term. The following balancing measures will
be included as a project outcome:
• Number of GP or practice nurse sessions changed or
cancelled to host the clinic
• Additional costs such as childcare or extra travel incurred
by the delivery team when care is delivered remote to their
usual place of work or outside the usual working week
• Number of additional GP, community nurse, or emergency
department episodes resulting from remote monitoring
• Number of additional secondary care referrals resulting
from the program
Discontinuation or Withdrawal of Participants from
Study Treatment
Participants may withdraw at any point in the study.
Definition of End of Study
The end of study is the 6-month follow-up after the
questionnaires are received from the last participant.
Data Analysis
Description of Analysis Populations
All patients recruited in the study will be included in the analysis
population.
Analysis of Quantitative Outcome Data
The objective of all analyses is to examine differences in
measured variables between time points.
The following comparisons will be made:
• Asthma Control Questionnaire, CAT, and AQLQ: baseline
as compared to 3 and 6 months
• Emergency care outcomes: 3 and 6 months prior to study
as compared to the 3- and 6-month study period
• Activation or medicine compliance (ASK-12 and Patient
Activation Measure): baseline as compared to 3 and 6
months
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• EuroQoL-5D and weight-bearing physical activity: baseline
as compared to 3 and 6 months
All the abovementioned variables are continuous measures.
Comparisons between time points will be made using the paired
t test or the Wilcoxon matched-pairs test, depending on the
distribution of the changes in outcome between time points.
Summaries of the measures of monitoring and supported
follow-up will be prepared (measures outlined above). Patient
satisfaction measures will be summarized descriptively.
Numbers and percentages will be used for categorical variables,
whereas mean and SD or median and interquartile range will
be used for continuous variables. Uncertainty in percentages,
means, and medians will be quantified by calculating the
appropriate 95% CIs.
Participatory Action Research
Periodic reviews of process measures and feedback may result
in iterative changes of the clinical model. The fidelity of clinic
delivery to the original plan will be presented and analyzed.
Procedure for Dealing With Missing, Unused, and
Spurious Data
Each outcome will be analyzed using measured data values of
all patients. Patients with missing data will be excluded from
the analyses. Suspicious data values will be checked against the
source data. If there are outlying values, the analyses will be
performed twice—once with the outlying values and once
without the outlying values.
Interim Analysis and Criteria for Early Study
Termination
No interim analyses are planned. A single analysis will be
performed when all patients have completed the study. The
study will not be terminated early based on any study data.
Patient Public Involvement
Study Design
The MISSION ABC clinic has been formed by feedback from
patients’ involvement in the prior pilots (MISSION Asthma and
MISSION COPD). All relevant outcomes of patients will be
recorded. All paperwork, such as Participant Information Sheets
and educational literature, is reviewed by our patient participants
before distribution.
Study Implementation
The steering group for MISSION ABC includes the chair of a
local Patient Action Group and patients from the MISSION
COPD pilot project and local Breathe Easy Groups. Ongoing
data such as those generated from the cyclical evaluation of
clinics will be reviewed, and the group will contribute to
informing and delivering change.
Dissemination
Lay summaries of the results of the research will be written
together with the Patient and Public Involvement members,
disseminated both in verbal and written formats to local groups
such as Breathe Easy groups, and written in appropriate formats
for the Trust social media accounts. The Patient and Public
Involvement members will be invited to present data locally
and nationally, where appropriate.
Results
The project was funded in 2017 and enrollment was completed
in 2018. Data analysis is currently underway, and the first results
are expected to be submitted for publication in April 2019.
Discussion
This is a unique participatory action research study using both
qualitative and qualitative methodology involving patients,
carers, and HCPs. The longer-term impact of the service will
be evaluated using clinical and health service outcomes that
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